<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839878</url>
  </required_header>
  <id_info>
    <org_study_id>INS-3738</org_study_id>
    <nct_id>NCT00839878</nct_id>
  </id_info>
  <brief_title>A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh</brief_title>
  <acronym>DiabCare Asia</acronym>
  <official_title>A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia DiabCare Asia 2008 (Bangladesh)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this observational study is to evaluate current
      status of diabetes management, control, complications in diabetic subjects in Asia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean age of onset of type 1 and 2 diabetes mellitus</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean duration of treatment of type 2 DM</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients on Insulin and OAD therapy</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean duration of diabetes in type 1 and type 2 patients respectively</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean FPG and PPG of diabetic patients</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean HbA1c of diabetic patients</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients with HbA1c target below or equal to 7.0%.</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients with HbA1c target below or equal to 6.5%.</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients having dyslipidemia and hypertension</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients having cardiovascular complications</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients having peripheral vascular disease</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients having diabetic eye complications</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of diabetic patients having diabetic nephropathy</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' perception will be analysed through Patient questionnaire measuring:Psychological well-being, Quality of life and Patients' compliant to treatment</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician perception of diabetes and its management will be analysed through physician questionnaire measuring awareness about HbA1c test and its goal, anti-diabetic treatment and barriers towards optimum diabetes control</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of diabetes associated with highest number of diabetic complications</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)</measure>
    <time_frame>at baseline visit/study start</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2092</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Subject will only fill out a questionaire when entering the observational study.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetes mellitus (both type 1 and type 2) being treated at general
        hospitals, diabetes clinics and referral clinics will be selected according to inclusion
        and exclusion criteria. Patients will be selected randomly from clinic record/ list to
        avoid any bias.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients registered in the particular centre for more than 12 months.

          -  Patients should have visited the centre at least once in the last 3-6 months apart
             from the initial visit.

          -  Patients willing to sign informed consent form.

        Exclusion Criteria:

          -  Repetition of any patient as patients should not be included twice for any reason.

          -  Unwilling to participate or unable to comply with protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dhaka</city>
        <zip>1206</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

